Hagop Kantarjian,MD @DrHKantarjian Twitter profile

Last Seen Profiles

@ZoroCoc

@lab_mari

@retro_bowl

@BlackHannity

@Nelorafal

@BewitchedInk

@syxmy_

@adeleabenionben

@MHS_Boys_

@2025Charlotte

@KVickers

@OluwafisayomiKD

@tpowersofficial

@bntrjl2

@1chan_meijin

@ciastkofelka

@theeczoo

@MOCHISUCK

@healthgiver

@xiao_kanat

@digitaesse

@mikaiart

@simgurujessica

@Remnant_Tales

@melbrewer367

@isogai_guitar

@ron_kda

@creyuz

@MontanAlavesa

@asisttime

@tonybulumanu

@cyberbeaner

@CadeMaddoxXx

@minami578314719

@Andriatic

@BrandtsBoysNash

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL. Jabbour, Short, Kantarjian of @MDAndersonNews #Leukemia via @TheLancetHaem #leusm

10

128

389

Hagop Kantarjian,MD

@DrHKantarjian

2 years

TP53 mut #MDS / #AML : Biology, Current Therapy, and Future Directions - state of the art review in @CD_AACR by @MDAndersonNews #Leukemia Naval Daver, MD, @Daver_Leukemia and Abhi Maiti, MD #leusm

3

63

194

Hagop Kantarjian,MD

@DrHKantarjian

4 months

Aza + ven + gilteritinib highly effective in newly dx older FLT3-mut #AML : CR/CRi 96% and 18-month OS 72%. A new standard of care in this population. @NicholasShortMD of @MDAndersonNews #Leukemia @JCO_ASCO #leusm

5

61

188

Hagop Kantarjian,MD

@DrHKantarjian

3 years

A combination of 2 targeted drugs, ponatinib+ blinatumomab, WITHOUT ANY CHEMOTHERAPY, results in 100% complete response rate, 85% complete molecular remission rate in newly diagnosed pts w/ Ph-positive #ALL . @MDAndersonNews study led by @NicholasShortMD & Jabbour #leusm #ASCO21

MD Anderson Cancer Center

@MDAndersonNews

3 years

A study led by our Dr. Elias Jabbour shows a chemo-free combination results in 100% complete response rate in newly diagnosed patients with Ph+ acute lymphoblastic leukemia. Dr. Nicholas Short presents the findings at #ASCO21 : @NicholasShortMD #EndCancer

6

20

139

2

41

186

Hagop Kantarjian,MD

@DrHKantarjian

11 months

Dasatinib 50 mg daily is as effective and less toxic than 100 mg daily for newly diagnosed CML-CP Georgina Gener-Ricos @FadiHaddad_MD @MDAndersonNews @OncologyAdvance #leusm #CML

9

47

184

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Ponatinib + Hyper-CVAD in Ph+ ALL = 6-yr OS 75%; no need for SCT if CMR. Another good standard of care. @MDAndersonNews #Leukemia via @AjHematology #leusm #ALL

4

50

178

Hagop Kantarjian,MD

@DrHKantarjian

2 years

NGS-based MRD (sensitivity: 1x10^-6) is superior to flow MRD in predicting ALL relapse. Rapid NGS MRD negativity should be the goal of any new #ALL therapy. Nicholas Short, MD, @NicholasShortMD , of @MDAndersonNews #Leukemia via @BloodAdvances #leusm

1

52

166

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Led by our @doctorpemm ➡Just out in @JCO_ASCO : Long-term favorable extended frontline efficacy outcomes for patients w/ #BPDCN treated w/SL-401 ( #CD123 -targeted) n=65;med age 68y[22-84];ORR 75% (CR/CRc =57%) #leusm #endcancer @MDAndersonNews

11

66

174

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Lower dose dasatinib 50 mg as good and less toxic than 100 mg in #CML . via @AjHematology #leusm

5

40

161

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Ph-positive #ALL therapy: Chemo-Free at Last? CMR rate of 86% and 2-year OS rate of 93% Published now in @JAMAOnc review from Elias Jabbour, MD, @FadiHaddad_MD , and @NicholasShortMD of @MDAndersonNews #Leukemia #leusm

3

36

161

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Lower-intensity regimens w/ venetoclax are safer and more effective than intensive chemotherapy for most older pts w/ #AML . Our new review in @LancetHaematology w/ @NicholasShortMD discusses our current approach for these patients. @MDAndersonNews #leusm

2

50

158

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Out now in @TheLancetHaem via @MDAndersonNews Leukemia | Outcomes of venetoclax combined with IC in #AML | VEN+IC👉 improved MRD-negative CR rates, transition to alloHSCT, and EFS compared to IC alone. #leusm

3

44

151

Hagop Kantarjian,MD

@DrHKantarjian

2 years

A fixed blast % to discriminate #MDS from #AML is overly simplistic. Patient characteristics and genomics are key factors to identify optimal therapy. Time to Blur the Blast Boundaries Courtney DiNardo MD, @garciamanero , @DrHKantarjian @MDAndersonNews

5

33

148

Hagop Kantarjian,MD

@DrHKantarjian

3 months

Gamma delta T cells are a novel immunotherapy for AML. Recent review from our group We have clinical trials w Aza Ven & gd2T cell activating ICT01 for Newly Dx AML, & allogeneic gd1T cells for R/R #AML #leusm

3

30

142

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Potential New Era in Myelofibrosis: Targeting #BCLxL : Navitoclax in combination w/ Ruxolitinib for patients with suboptimal response/progression of MF: Ph2 Results @doctorpemm @MDAndersonNews via @ASCOPost #SergeVertovsek #MPNSM

4

57

141

Hagop Kantarjian,MD

@DrHKantarjian

8 months

Treatment of FLT3-mutated #AML in older pts remains a challenge. New HMA + venetoclax + FLT3 inhibitor triplet regimens may improve outcomes. @NicholasShortMD of @MDAndersonNews #Leukemia @BloodCancerJnl #leusm

3

39

131

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Most leukemias functionally or molecularly curable with current therapies. Good reading for deeper dive. @NitinJainMD , @garciamanero , @wwierda and colleagues @MDAndersonNews | via @JournalCancer #leusm

3

33

134

Hagop Kantarjian,MD

@DrHKantarjian

1 year

The latest targeted therapy in leukemia. First clinical evidence of responses with menin inhibitors in very resistant leukemias Ghayas Issa @GhayasIssa of @MDAndersonNews #Leukemia @Nature #leusm

1

31

130

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Addition of Navitoclax (BCLxL inhibitor) to Ruxo in patients with MF ➡ clinically favorable results w/novel biomarker analysis led by @doctorpemm @MDAndersonNews in @TheLancetHaem | #MPNSM #endcancer

5

50

129

Hagop Kantarjian,MD

@DrHKantarjian

1 year

In older pts with #AML , low-intensity therapy + ven followed by SCT 2-year OS of 72% and lower NRM than intensive chemo. LIT + ven induction is good option even for SCT-eligible pts. @NicholasShortMD @MDAndersonNews #Leukemia #leusm

3

51

126

Hagop Kantarjian,MD

@DrHKantarjian

2 years

How We Incorporate Venetoclax in Treatment Regimens for #AML - Maximizing Efficacy and Minimizing Toxicities Abhishek Maiti, MBBS, Marina Konopleva, MD, PhD | @MDAndersonNews via @PPO_journal_lww #leusm

0

24

123

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Menin inhibitors could be the next breakthrough in treatment of MLLr or NPM1+ leukemias. @LeukemiaJnl (2021) | Study led by @GhayasIssa of @MDAndersonNews | | #leusm #AML

0

25

122

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Published now in @JCO_ASCO from @MDAndersonNews Leukemia | CLAD/LDAC/VEN alternating with AZA/VEN in older #AML ➡️ CR/CRi 93%, MRD neg 84%!! 2-yr CR duration 76% and 2-yr OS 64%! Potentially practice changing regimen. #leusm

2

35

124

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Pts with Ph+ ALL who are MRD negative by NGS but PCR+ for BCR::ABL1 have very low risk of relapse. NGS may be the best assay for monitoring MRD in Ph+ ALL @NicholasShortMD Elias Jabbour @MDAndersonNews #Leukemia @AjHematology #leusm

2

43

124

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Marking 10+ yrs since pioneering approval of first JAKi monotherapy for MF. Highlighting now exciting start of new era of combination therapy using JAKi as therapeutic backbone @doctorpemm et al @bose_prithviraj @raajitrampal @MDAndersonNews #Leukemia

4

46

122

Hagop Kantarjian,MD

@DrHKantarjian

1 year

#CML with no MMR after 2 years of TKI is not adverse. Favorable outcomes are seen even with BCR::ABL 1-10% @AbidikianMD @MDAndersonNews #Leukemia via @AjHematology #leusm

1

32

116

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Multinational randomized trial of ibrutinib + venetoclax in #CLL confirms the initial pilot trial results from @MDAndersonnews of high rate of disease elimination with a oral targeted therapy of finite treatment duration | W. Wierda @wwierda via @JCO_ASCO

3

24

118

Hagop Kantarjian,MD

@DrHKantarjian

1 month

Low-dose azacitidine plus venetoclax maintains remissions with manageable side effects in patients with #AML unable to complete standard consolidation strategies (2-year modified RFS and OS of 56% and 72%). @MDAndersonNews #Leukemia @TheLancetHaem #leusm

4

39

116

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Now we have menin inhibitors that should improve KMT2A (MLL) #leukemia outcome Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience @MDAndersonNews via @BloodAdvances | #leusm #ALL

0

28

116

Hagop Kantarjian,MD

@DrHKantarjian

8 months

Combo of venetoclax+ hypomethylating agent = high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated #AML @Nature @MDAndersonNews #leusm

2

32

117

Hagop Kantarjian,MD

@DrHKantarjian

2 years

FDA confirms CR and EFS correlate with OS in #AML and of value as surrogate trial endpoints = should translate into faster AML trial timelines to bring effective therapies to AML | Courtney DiNardo, MD & @DanPollyea | via @JCO_ASCO #leusm @MDAndersonNews

1

29

116

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Congratulations to Courtney D. DiNardo, M.D., on her publication of 'Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid #Leukemia '. | #leusm #AML

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly...

PURPOSE Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested...

ascopubs.org

2

23

111

Hagop Kantarjian,MD

@DrHKantarjian

2 years

FLT3-mutated #AML is not adverse anymore in the modern era of AML Rx incorporating better intensive regimens/FLT3 inhibitors/SCT @patrickreville and @TapKadia @MDAndersonNews @AjHematology #leusm

0

28

112

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Karnofsky top @ASCO award recognizes @MDAndersonNews #Leukemia Faculty team research and excellence. 10 are among top 15 world leukemia researchers. #leusm #EndCancer #ASCO2023

11

13

113

Hagop Kantarjian,MD

@DrHKantarjian

3 years

New model to predict 4-week mortality with intensive chemotherapy in #AML , and to propose therapy accordingly Sasaki, Kadia, Et al. | @MDAndersonNews | via @WileyOnc_Hem #leusm #leukemia

0

30

110

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Nice review by @NicholasShortMD and colleagues on the prognostic and therapeutic impact of MRD in #AML . Enrollment of patients with MRD+ AML on clinical trials is imperative to improve outcomes. #leusm #leukemia

1

25

107

Hagop Kantarjian,MD

@DrHKantarjian

9 months

Highlighting start of a new era beyond JAK inhibitor monotherapy in MF: Focus on novel #BCLXL inhibitor combinations | led by @doctorpemm of @MDAnderson #Leukemia in @JournalCancer #mpnsm

New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy:...

Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.

acsjournals.onlinelibrary.wiley.com

4

41

103

Hagop Kantarjian,MD

@DrHKantarjian

2 years

New meta-analysis: MRD highly prognostic in #AML , regardless of type of response (CR vs. others) or assay sensitivity. More evidence that MRD could be surrogate endpoint in AML | @NicholasShortMD @MDAndersonNews #Leukemia @LeukemiaJnl #leusm

2

41

105

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Very exciting new treatment options in #AML Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid #Leukemia | Andrew H. Wei, MBBS, PhD; Gail J. Roboz , MD; and Hagop M. Kantarjian, MD | via @ASCO_pubs #leusm

2

19

103

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Non-Chemo regimen of venetoclax + gilteritinib highly active in R/R FLT3+ AML (including exposed to prior FLT3 inhibitors). Published now @JCO_ASCO #leusm #AML

1

29

101

Hagop Kantarjian,MD

@DrHKantarjian

10 months

In #CML with T315I mutation, being in chronic phase at the time of mutation detection, and treatment with ponatinib/asciminib or transplant, are associated with improved long-term survival @FadiHaddad_MD @MDAndersonNews #Leukemia @AjHematology #leusm

4

27

103

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Check the largest single-institution experience reported on treatment-free remission (TFR) in #CML --> Deep molecular remission for 5 + years associated with the highest chance (80+%) of successful TFR. @MDAndersonNews @FadyyHaddad @AjHematology #leusm

3

26

101

Hagop Kantarjian,MD

@DrHKantarjian

5 months

Arsenic trioxide 0.15 mg/kg without capping (15 mg maximum dose cap) may cause renal damage in obese patients with APL @MDAndersonNews @jenweiying @TapKadia @GBorthakur @MusaYilmazMD @fravandi1 Leukemia & Lymphoma

Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic...

Arsenic trioxide (ATO)-based regimens are standard in acute promyelocytic leukemia (APL). ATO-related nephrotoxicity has not been reported. We reviewed APL patients treated with ATO to identify cas...

www.tandfonline.com

3

28

100

Hagop Kantarjian,MD

@DrHKantarjian

3 years

So gratifying to see this great man honored by @ASCO with highest honors. Dr. Freireich was a great physician, scientist, mentor and friend and personally mentored hundreds of our current thought leaders throughout oncology and hematology. @MDAndersonNews #leusm #leukemia

0

19

100

Hagop Kantarjian,MD

@DrHKantarjian

10 months

Important, multi-disciplinary, joint pediatric/adult leukemia group effort led by our Drs @CuglievanBranko & @doctorpemm → highlighting new era of research & discovery for #BPDCN in #pediatric and #AYA patients @LeukemiaJnl @MDAndersonNews

4

33

100

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Remembering Dr. Freireich, of @MDAndersonNews , a giant in cancer research. Remembering Emil J. Freireich: A Portrait of Courage and Innovation in Cancer Research—March 16, 1927 to February 1, 2021 via @ASCO_pubs #leukemia #leusm

3

36

101

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Novel targeted therapies like enasidenib (IDH2 inhibitor) added to standards of care are improving #AML outcomes via @TheLancetOncol | Courtney D DiNardo, MD, H M Kantarjian, MD, of @MDAndersonNews #Leukemia #leusm

0

17

99

Hagop Kantarjian,MD

@DrHKantarjian

4 months

Dose-dense mini-hyper-CVD, INO and blina achieves NGS MRD negativity in >90% of pts with new dx B-ALL. A clinical trial at @MDAndersonNews is ongoing. @NicholasShortMD Clinical Lymphoma, Myeloma and Leukemia

3

21

99

Hagop Kantarjian,MD

@DrHKantarjian

7 months

Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%. Elias Jabbour, @FadiHaddad_MD @DrHKantarjian of @MDAndersonNews #Leukemia @ASH_Hematology #ALL #leusm

3

19

96

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Therapy of older/unfit #AML rapidly improving and changing from intensive chemotherapy to highly effective low intensity targeted tolerable therapies via @ASCO_pubs | Nicholas Short, @NicholasShortMD & Hagop Kantarjian of @MDAndersonNews #leukemia #leusm

0

22

95

Hagop Kantarjian,MD

@DrHKantarjian

2 years

HCVAD chemotherapy ➡Still plays an important role in Tx of #BPDCN , even in era of #CD123 -targeted therapy; high response rates, incorporation of CNS-directed Tx, offering possibilities for combination/total Tx approaches in #BPDCN | @doctorpemm

0

18

93

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Our new paper by @NicholasShortMD in @AjHematology reviews the decades of clinical research and dose optimization of HMAs in #MDS and #AML . Novel combinations and oral formulations are now expanding the role of HMAs in myeloid diseases. #leusm

0

18

90

Hagop Kantarjian,MD

@DrHKantarjian

1 year

A new model to predict survival after low-intensity chemoRx in older #AML published by Dr. Koji Sasaki of @MDAndersonNews #Leukemia , @JournalCancer online #leusm

5

29

86

Hagop Kantarjian,MD

@DrHKantarjian

9 months

Join us in welcoming Alexandre Bazinet, MDCM, MSc to our @MDAndersonNews #Leukemia Faculty! Dr. Bazinet first joined MD Anderson in 2021 as a fellow. We are pleased to have him on our team. #leusm #EndCancer

2

4

91

Hagop Kantarjian,MD

@DrHKantarjian

4 years

See our recent paper : updating our outstanding HyperCVAD results in adult ALL including tips on how to optimize results and minimize toxicity. @TapKadia @LeukemiaMDA @MDAndersonNews ; #ALL

0

27

87

Hagop Kantarjian,MD

@DrHKantarjian

11 months

The field of #BPDCN is rapidly evolving | Our new article by Dr. Pemmaraju @doctorpemm highlights the new era of targeting #CD123 in combinations & beyond @MDAndersonNews @clinadvances

4

35

87

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Discussing treatment choices and endpoints in #CML : what is best for the patient in 2023? Please check out our review just published in @BloodCancerJnl . @jayastuMD of @MDAndersonNews #Leukemia #leusm

0

23

89

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Sharing our new major effort: North American #BPDCN Consortium to highlight increased collaboration & novel patient-based research approaches | Pemmaraju of @MDAndersonNews #Leukemia | via @BloodJournal @ASH_hematology #leusm

2

29

87

Hagop Kantarjian,MD

@DrHKantarjian

7 months

Failing TKI treatment milestones (ELN, NCCN) not that adverse; may not need to change TKI Rx in most patients Hagop Kantarjian, MD of @MDAndersonNews #Leukemia @LeukemiaJnl #leusm #CML

3

18

86

Hagop Kantarjian,MD

@DrHKantarjian

4 years

Exceptional results with mini hyper-CVD + inotuzumab + blinatumomab in older ALL and ALL salvage. ; ; ;

Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With...

ascopubs.org

0

28

82

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Novel frontiers in older/unfit #AML therapy -- we should avoid the use of intensive chemotherapy in most patients >60 years of age | via @ASCO_pubs | Nicholas Short, @NicholasShortMD & Hagop Kantarjian of @MDAndersonNews | #leusm #leukemia

0

25

82

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Outcomes of NPM1+ #AML at relapse are not favorable. Recommend new therapies such as menin inhibitors. @GhayasIssa @ABidikianMD @Daver_Leukemia of @MDAndersonNews #Leukemia via @ASH_hematology @BloodAdvances #ASH22 #leusm

1

24

84

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Mini-HyperCVD-Inotuzumab +/- blinatumomab shows a promising 5-year OS of 46 % in newly diagnosed older patients (>/=60 years) with Ph negative B-cell ALL. Elias Jabbour @NicholasShortMD @jayastuMD @MDAndersonNews #Leukemia @TheLancetHaem #leusm #ALL

1

18

83

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Thank you Dr. Khuri @DrFadloKhuri . @AUB_Lebanon is fortunate to have you leading this luminary top Middle East institution.

Dr. Fadlo Khuri

@DrFadloKhuri

1 year

Our ⁦ @AUB_Lebanon ⁩ 2019 graduation was the occasion we awarded two time alumnus and former Internal Medicine Chief resident ⁦ @DrHKantarjian ⁩ an honorary doctorate. Hagop is a hero for leukemia patients and a role model for oncologists and hematologists everywhere.

2

3

83

6

8

83

Hagop Kantarjian,MD

@DrHKantarjian

2 years

📢Out now in @AjHematology via @MDAndersonNews #Leukemia 👉 Extended follow up (median 20 mo.) with expanded enrollment (N=45) of FLAG-IDA-VEN in ND-AML | ORR: 98% | CRc: 89% | ⏫ MRD-neg CRc: 93%| 24-month OS 85% in ELN adv. risk w/o TP53 mut. Link👇

0

23

80

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Hypercvad and blinatumomab = 3-year OS 80+%; much better than historical | Elias Jabbour, Nicholas Short, @NicholasShortMD , Hagop Kantarjian, of @MDAndersonNews #Leukemia | via @TheLancetHaem #leusm #ALL

2

27

80

Hagop Kantarjian,MD

@DrHKantarjian

3 years

"Harnessing the benefits of available targeted therapies in acute myeloid leukaemia": via @TheLancetHaem | #Leukemia #leusm #AML

0

4

81

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Join our @MDAndersonNews Emil J Freireich Hematology Grand Rounds as I present “What is new at ASH and Leukemia 2022” | Dec. 15, 2021 8 am CST | | #leusm #MedEd #ASH21

1

13

79

Hagop Kantarjian,MD

@DrHKantarjian

4 months

Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated R/R #ALL . Study now amended to add navitoclax (BCL-xL inhibitor). @ASH_Hematology @BloodAdvances @MDAndersonNews #leusm

3

23

77

Hagop Kantarjian,MD

@DrHKantarjian

11 months

Key Paper in treatment of Older AML ➡️out in @AjHematology Incorporation of venetoclax-based therapy & increased utilization of Allo SCT has led to higher rates of quality remissions & significant improvement in OS for patients aged > 60 years. @Tapkadia

1

22

77

Hagop Kantarjian,MD

@DrHKantarjian

3 months

In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate & an acceptable safety profile in heavily pretreated adults w/ R/R B-ALL Elias Jabbour of @MDAndersonNews #Leukemia @AjHematology #leusm

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.

onlinelibrary.wiley.com

2

23

77

Hagop Kantarjian,MD

@DrHKantarjian

9 months

New comprehensive review by @NicholasShortMD , @JayastuMD and Dr. Elias Jabbour of @MDAndersonNews #Leukemia discusses state-of-the-art management of advanced phase #CML . #leusm

0

19

78

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Prolonged exposure to blina is associated w/ favorable outcomes in pts w/ MRD positive B-ALL at a threshold of 10-4 or more & may spare the need for allogeneic SCT w/ 73% of pts achieving MRD negative remission and 3-year RFS and OS rates of 63% and 67%.

2

16

77

Hagop Kantarjian,MD

@DrHKantarjian

2 years

New discovery from the MDS group in the @MDAndersonNews Department of #Leukemia ! Congratulations to Simona, Guillermo @garciamanero and collaborators. via @BCD_AACR #leusm

2

16

70

Hagop Kantarjian,MD

@DrHKantarjian

1 year

Led by our own Dr. Verstovsek of @MDAndersonNews #Leukemia , important Ph3 study MOMENTUM: Momelotinib vs danazol resulted in clinically significant improvements in MF-associated anemia+sxs+spleen response+favorable safety. @TheLancet #MPNSM

3

20

74

Hagop Kantarjian,MD

@DrHKantarjian

10 months

@MDAndersonNews #Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed #AML | @BloodJournal #leusm

2

20

71

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Join the @UTHealthHouston Hematology and Oncology Grand Rounds as I present "Therapy and Research in Acute Lymphoblastic #Leukemia in 2021" | Monday, August 30, 8 am CST | Zoom Attendance Only #leusm #MedEd #ALL

1

18

72

Hagop Kantarjian,MD

@DrHKantarjian

1 year

New review on state-of-the-art treatment of advanced phase #CML (AP/BP) by @JayastuMD and @NicholasShort of @MDAndersonNews #Leukemia , published in @LeukemiaJnl . We prefer ponatinib-based combo regimens for these pts whenever possible. #leusm

1

33

73

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Generic imatinib at $47/month directly from manufacturer = more patients with #CML can afford treatment and live normal life via @TheLancetHaem #leusm

1

15

72

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Thrombosomes, if validated to be as beneficial or superior to platelet transfusions in thrombocytopenia/bleeding, can be the best solution to platelet shortages, & replace them in thrombocytopenia/bleeding Maro Ohanian, DO @MDAndersonNews via @AjHematology

0

14

70

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Combination of non-chemo therapy/ dual targeted therapy with bosutinib-inotuzumab shows excellent results in Ph+ ALL/CML lymphoid BP | | #EndCancer #leusm #ALL #CML

0

14

71

Hagop Kantarjian,MD

@DrHKantarjian

9 months

Now out in @Ajhematology reporting Ph II trial of CLIA +/-Sorafenib in newly diagnosed #AML . With a median F/U of 76 months, CR/CRi Overall was 83% (74% MRD neg) & 4-yr OS of 57%; Among FLT3-ITD, CR/CRi was 95% (81% MRD neg), w/ 5-yr OS of 59%. @TapKadia

2

13

71

Hagop Kantarjian,MD

@DrHKantarjian

5 months

Updates on the management of Ph-positive #ALL , the role of ASCT, MRD monitoring, and future therapies Clinical Lymphoma, Myeloma and Leukemia @FadiHaddad_MD , Elias Jabbour, @NicholasShortMD , @NitinJainMD , @DrHKantarjian of @MDAndersonNews #Leukemia #leusm

1

18

70

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Join our virtual @MDAndersonNews Emil J Freireich Hematology Grand Rounds as I present “CML in 2022- Current Status and Research Directions” | April 6, 2022 8 am CST | | #leusm #MedEd #CML

0

10

69

Hagop Kantarjian,MD

@DrHKantarjian

2 months

In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. Alexandre Bazinet, @garciamanero , @fravandi1 @MDAndersonNews #Leukemia @TheLancetHaem #leusm #AML

2

18

68

Hagop Kantarjian,MD

@DrHKantarjian

4 years

Update on COVID-19 pandemic. I am cautiously optimistic.

Research Library | Baker Institute

www.bakerinstitute.org

1

29

64

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Please join our @MDAndersonNews Emil J Freireich Hematology Grand Rounds: “Chimeric Antigen Receptor T-cell Therapy for Hematologic Malignancies” presented by Jim Kochenderfer, M.D., of @NCIResearchCtr | May 5, 8 am CST | | #leusm #MedEd #CART

1

12

67

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Join our @MDAndersonNews Emil J Freireich Hematology Grand Rounds: “Integrated TP53 Evaluation in Acute Myeloid #Leukemia ” presented by Joseph Khoury, MD, FCAP @JoeKhouryMD | Jan. 5, 2022 8 am CST | | #leusm #MedEd #AML

3

15

65

Hagop Kantarjian,MD

@DrHKantarjian

1 year

MiniCVD-INO-BLINA in #ALL salvage new standard of care. OOR 83%; 3-yr OS 40%, 52% when both INO-BLINA used, 49% is S1. Kantarjian @FadiHaddad_MD Jabbour @MDAndersonNews #Leukemia @SN_Oncology #leusm

0

27

63

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Hematologic Malignancies Demystified 2022: Important Updates in Hematologic Malignancies JANUARY 29, 2022 | FEBRUARY 5, 2022 Register at #HMDlive22 #leusm

2

11

64

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Published now @BloodCancerJNL 📢 Triplets (LIC+VEN+FLT3i) outperforms doublets (LIC+FLT3i) in frontline older/unfit FLT3m #AML . CR/CRi, MFC negativity, and the 2-year OS rates ➡ 93% vs. 70%, 83% vs. 38%, and 70% vs. 22% 👇 @MusaYilmazMD @DaverLeukemia

2

22

63

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Post #SOHO22 Wrap up: Wonderful meeting & fantastic international engagement for #SOHO2022 2,152 attendees, 124 countries represented, 468 posters presented, & 121 speakers. Save the date for Sept 6-9, 2023 & join us next year: #leusm #lymsm #mmsm #bmtsm

2

7

64

Hagop Kantarjian,MD

@DrHKantarjian

2 months

Pivekimab, novel CD123 antibody drug conjugate, demonstrates safety & efficacy in R-R AML. Frontline single agent PVEK in BPDCN (CADENZA) & AZA/VEN/PVEK in frontline older #AML ongoing @Daver_Leukemia @doctorpemm @MDAndersonNews - @TheLancetOncol #leusm

0

17

63

Hagop Kantarjian,MD

@DrHKantarjian

3 years

Join our @MDAndersonNews Emil J Freireich Hematology Grand Rounds: “Progress in Frontline #AML Treatment at MD Anderson" presented by Tapan Kadia, M.D., @TapKadia | Sept. 1, 2021 8 am CST | | #leusm #MedEd #leukemia

1

12

62

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Patients refractory to multiple tx with KMT2Ar/NPM1 acute leukemias responded to the menin inhibitor SNDX-5613 with high MRD-neg rates. Trial @mdanderson led by @ghayasissa #leusm #ASH21

0

9

61

Hagop Kantarjian,MD

@DrHKantarjian

2 years

Congratulations to Dr. Garcia-Manero, @garciamanero of @MDAndersonNews #Leukemia , who was honored with the Emil Freireich Distinguished Pioneer Award from the @SocietyofHemOnc . Guillermo is a pioneer in the footsteps of Dr. Freireich. #leusm #SOHO2022

Hematologic Oncology News | Blood Cancers Today

Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices, featuring exclusive expert interviews.

bloodcancerstoday.com

0

5

60

Hagop Kantarjian,MD

@DrHKantarjian

25 days

Tagraxofusp is a first-in-class CD123-directed drug which has changed the field of #BPDCN . We review the evidence leading to its approval, use in combos and newer CD123 agents. @jenweiying @doctorpemm @mkonople @MDAndersonNews #Leukemia @JournalCancer

Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of...

Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.

acsjournals.onlinelibrary.wiley.com

2

30

60

Hagop Kantarjian,MD

@DrHKantarjian

3 months

The response-based dosing of ponatinib in OPTIC substantially improves cardiovascular risk without compromising efficacy in patients with difficult-to-treat CP-CML. Elias Jabbour of @MDAndersonNews #Leukemia @LeukemiaJnl

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia...

Leukemia - Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

www.nature.com

1

18

59

Hagop Kantarjian,MD

@DrHKantarjian

26 days

Dasatinib + Venetoclax is safe & effective in newly diagnosed #CML in CP, but no better than single-agent dasatinib; longer follow-up needed to evaluate impact on TFR: @MDAndersonNews #Leukemia @JournalCancer

1

10

60

Hagop Kantarjian,MD

@DrHKantarjian

10 months

Our study of aza + ven + pevonedistat NEDD8-activating enzyme inhibitor in secondary AML & MDS/CMML after HMA failure. High response rates in poor-risk population. Data from randomized ph3 study in #AML are awaited. @NicholasShortMD @SN_Oncology #leusm

3

17

58